- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer hurt by drop in OEM shipments
A sharp drop in product shipments to OEMs in the fourth quarterstung x-ray vendor Fischer Imaging, which reported disappointingyear-end and fourth-quarter financial results last week. The Denvercompany said that a decline in shipments of its Tilt-C C-arm
A sharp drop in product shipments to OEMs in the fourth quarterstung x-ray vendor Fischer Imaging, which reported disappointingyear-end and fourth-quarter financial results last week. The Denvercompany said that a decline in shipments of its Tilt-C C-arm toGE Medical Systems contributed to a 50% drop in OEM sales forthe fourth quarter.
For the year (end-December), Fischer posted revenues of $77.5million, up slightly from revenues of $76.8 million in 1995. Thecompany had a net loss for the year of $361,000, compared withnet income of $2.3 million in 1995.
Fischer's slide was even worse in the fourth quarter, when thecompany recorded revenues of $14.6 million, down 36% comparedwith sales of $23 million in the same period the year before.The vendor's net loss for the most recent quarter was $2.6 million,compared with net income of $1.5 million in the fourth quarterof 1995.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
